Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
127 participants
OBSERVATIONAL
2009-06-30
2011-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Mechanisms of Acute Asthma Exacerbations Through Molecular Analysis of Airway Secretions and Tissues
NCT00603629
Characteristics of Type 2- High Inflammatory Endotype of Asthma Using New Biomarkers From Peripheral Blood and Exhaled Air and Its Effect on the Outcome of Therapy
NCT05270278
Biomarkers in Exhaled Breath From Asthmatic Patients
NCT00635271
The Role of Biomarkers in the Occurrence and Development of Asthma
NCT05768399
Blood Lymphocytes in Asthmatics Treated With Therapeutic Proteins
NCT04514926
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthy, Non-asthmatic
No interventions assigned to this group
Asthma
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Physician diagnosis of asthma
3. PC20FEV1 methacholine ≤ 8.0 mg/mL, except for those taking daily inhaled corticosteroids, for which the PC20 methacholine should be \< 16 mg/mL.
4. Ability to provide informed consent.
1. Healthy male and female subjects with no history of asthma between the ages of 18 and 70 years. Subjects should not be taking inhaled or oral corticosteroids.
2. No lifetime history of asthma or allergic rhinitis.
3. Ability to provide informed consent.
Exclusion Criteria
2. History of an upper or lower respiratory tract infection in the 4 weeks preceding the study.
3. Females who are pregnant or breast-feeding
4. Subjects must be non-smokers (patients who have never smoked or patients who have smoked ≤5 cigarettes per month and have a total pack-year smoking history \< 10 packs).
5. Use of marijuana \>1 time per month in the last year and use of marijuana in the 6 weeks prior to enrollment
6. Use of recreational drugs other than marijuana in the 12 months preceding the study.
7. Use of Beta blocker medications
18 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Genentech, Inc.
INDUSTRY
University of California, San Francisco
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UCSF Airway Clinical Research Center
San Francisco, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H6788-34128-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.